Skip to content

Multispectral Optoacoustic Tomography for Advanced Imaging of Centronuclear Myopathy

Multispectral Optoacoustic Tomography for Advanced Imaging of Centronuclear Myopathy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07021820
Acronym
MOSAIC
Enrollment
40
Registered
2025-06-15
Start date
2025-05-29
Completion date
2026-12-31
Last updated
2025-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Centronuclear Myopathy

Keywords

MSOT, centronuclear myopathy, MOSAIC

Brief summary

Twenty patients with centronuclear myopathy and twenty age- and sex-matched, muscle-healthy controls will undergo diagnostic examination. Study participants will undergo physical examination, clinical and functional testing, and multispectral optoacoustic tomography (MSOT) scanning at predefined muscle sites (paraspinal muscles, trapezius muscle, deltoid muscle, forearm flexors, quadriceps muscle, adductor muscles, ischiocrural muscles, triceps surae muscle, and tibialis anterior).

Detailed description

Centronuclear myopathy (CNM) belongs to the group of congenital myopathies. These are named after their histopathological feature: the nucleus is localized in the center of the muscle cell instead of its physiological position at the periphery. CNM is so rare that there are only epidemiological data available for the group of congenital myopathies as a whole. The incidence is estimated at 0.06 per 1,000 live births. CNM is genetically and clinically heterogeneous. Identified gene mutations affect proteins involved in membrane remodeling, transport, and excitation-contraction coupling. Patients with CNM usually present with muscle weakness and hypotonia in early childhood. The severity of the disease varies depending on the underlying genotype and ranges from reduced exercise tolerance and ptosis to floppy infant syndrome and respiratory failure. One example of a very severe course is the X-linked form caused by a Myotubularin 1 (MTM1) nonsense mutation (XL-MTM). Affected patients become symptomatic in the neonatal period and usually die in childhood or adolescence. In contrast, patients with the Dynamin 2 (DNM2) mutation have a later onset and milder disease progression. In the few reported patients with Bridging Integrator 1 (BIN1) mutations, onset occurs in infancy or adulthood with a moderate disease course. Ryanodine receptor 1 (RYR1)-associated CNMs also vary in terms of age of onset and disease severity. Diagnosis is based on molecular genetic testing and muscle biopsy. However, these techniques are not widely available, are time-consuming, and invasive. Anesthesia is usually required for young patients. Multispectral optoacoustic tomography (MSOT) enables the detection of specific endogenous chromophores such as collagen, myoglobin, or hemoglobin using a non-invasive approach comparable to conventional ultrasound. Instead of sound waves, MSOT uses near-infrared light pulses that are absorbed by tissue, causing thermoelastic expansion of certain molecules. This expansion generates ultrasound waves, which are then detected by the same device. The multispectral illumination and signal unmixing enable precise localization and quantification of muscle-specific subcellular structures. MSOT has already demonstrated the potential to visualize muscle structure and disease extent in patients with Duchenne muscular dystrophy, spinal muscular atrophy, and late-onset Pompe disease (LOPD), and to distinguish these patients from healthy volunteers. To date, there are no optoacoustic data available for CNM. The aim of this study is to gain molecular insights into muscle degeneration in CNM patients for the first time. To develop a comprehensive picture of the optoacoustic characteristics of CNM, patients of different ages and disease severities will be recruited. Due to the rarity and small number of CNM cases, recruitment is challenging. Therefore, the opportunity should be taken to offer study participation to as many patients as possible at the patient meeting in Bad Nauheim from May 29 to June 1, 2025. In addition to non-invasive, radiation-free imaging, clinical-functional tests will be conducted as part of the study. These include muscle strength testing (MRC score) and the timed get up and go test. Various accessible muscle groups will be scanned using MSOT, including the paraspinal muscles and trapezius muscle, as well as the following limb muscles on both sides: deltoid, biceps brachii, forearm flexors, quadriceps femoris, adductors, hamstrings (ischiocrural muscles), triceps surae, and tibialis anterior.

Interventions

DIAGNOSTIC_TESTMSOT

Multispectral optoacoustic tomography (MSOT) enables the detection of specific endogenous chromophores such as collagen, myoglobin or haemoglobin using a non-invasive approach comparable to conventional ultrasound. Instead of sound waves, MSOT illuminates the tissue with near-infrared light of transient energy, which is absorbed and leads to thermoelastic expansion of certain molecules. This expansion generates ultrasound waves that are detected by the same device. The multispectral illumination and unmixing then enable the precise localization and quantification of muscle-specific subcellular structures. MSOT has already shown the potential to visualize the muscle structure and clinical extent of muscle disease in patients with Duchenne muscular dystrophy, spinal muscular atrophy and the late-onset Pompe disease (LOPD) and to distinguish these patients from healthy volunteers. To date, there is no optoacoustic data on CNM.

Sponsors

University of Erlangen-Nürnberg Medical School
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
2 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

CNM arm: Inclusion Criteria: diagnosed CNM; minimum of 2 years of age

Exclusion criteria

* Pregnancy * Nursing mothers * Tattoo in the area of the examination field * Subcutaneous fatty tissue \> 3 cm HV: Inclusion criteria: minimum of 2 years of age

Design outcomes

Primary

MeasureTime frameDescription
Optoacoustic spectrum of MSOT Imaging (all in arbitrary units)Day 1Comparison of optoacoustic spectrum from patients with diagnosed CNM and their age- and sex matched Healthy Volunteers

Secondary

MeasureTime frameDescription
Comparison of Oxygenated vs. Deoxygenated Hemoglobin SignalDay 1Quantitative comparison of oxygenated and deoxygenated hemoglobin signals.
Comparison of Oxygenated Hemoglobin and Lipid SignalDay 1Quantitative comparison of oxygenated hemoglobin and lipid signals.
Comparison of deoxygenated Hemoglobin and Lipid SignalDay 1Quantitative comparison of deoxygenated hemoglobin and lipid signals.
Comparison of oxygenated Hemoglobin and Collagen SignalDay 1Quantitative comparison of oxygenated hemoglobin and collagen signals.
Comparison of deoxygenated Hemoglobin and Collagen SignalDay 1Quantitative comparison of deoxygenated hemoglobin and collagen signals.
Comparison of Lipid and Collagen SignalDay 1Quantitative comparison of Lipid and collagen signals.
Comparison of Lipid and Myoglobin SignalDay 1Quantitative comparison of Lipid and Myoglobin signals.
Comparison of Collagen and Myoglobin SignalDay 1Quantitative comparison of Collagen and Myoglobin signals.
Correlation of Hemoglobin Signal with Disease Duration and Patient AgeDay 1Unit of Measure: Correlation coefficient (Pearson's r or Spearman's ρ)
Comparison of MSOT-Derived Hemoglobin and Myoglobin SignalsDay 1Quantitative comparison of MSOT-derived hemoglobin and myoglobin signals (arbitrary units).
Correlation of oxygenated and deoxygenated Hemoglobin Signal with Disease Duration and Patient AgeDay 1Unit of Measure: Correlation coefficient (Pearson's r or Spearman's ρ)
Correlation of Lipid Signal with Disease Duration and Patient AgeDay 1Unit of Measure: Correlation coefficient (Pearson's r or Spearman's ρ)
Correlation of Collagen Signal with Disease Duration and Patient AgeDay 1Unit of Measure: Correlation coefficient (Pearson's r or Spearman's ρ)
Correlation of Hemoglobin Signal with MRC Muscle StrengthDay 1Unit of Measure: Correlation coefficient (MRC scale: ordinal, 1-5)
Correlation of Myoglobin Signal with MRC Muscle StrengthDay 1Unit of Measure: Correlation coefficient (MRC scale: ordinal, 1-5)
Correlation of oxygenated and dexoygenated Hemoglobin with MRC Muscle StrengthDay 1Unit of Measure: Correlation coefficient (MRC scale: ordinal, 1-5)
Correlation of Lipid Signal with MRC Muscle StrengthDay 1Unit of Measure: Correlation coefficient (MRC scale: ordinal, 1-5)
Correlation of Collagen Signal with MRC Muscle StrengthDay 1Unit of Measure: Correlation coefficient (MRC scale: ordinal, 1-5)
Correlation of Myoglobin Signal with Disease Duration and Patient AgeDay 1Unit of Measure: Correlation coefficient (Pearson's r or Spearman's ρ)

Countries

Germany

Contacts

Primary ContactLina Tan
Lina.Tan@uk-erlangen.de+49 9131 85-41277

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026